Barrick Gold Corp (ABX) Given Average Recommendation of "Hold" by Analysts

Comparatively, 70.6% of Royal Gold shares are held by institutional investors. The company was maintained on Thursday, May 25 by RBC Capital Markets.

It is now trading at $15.43 slightly below $16.03, the stock's 50 day moving average and just below the 200 day moving average of $17.59. About 3,684 shares traded.

Barrick Gold Corp (TSE ABX) traded up 3.94% on Tuesday, reaching $20.05. It has underperformed by 16.70% the S&P500.

Causeway Capital Management Llc decreased its stake in Ubs Group Ag (UBS) by 8.03% based on its latest 2016Q4 regulatory filing with the SEC. Arlington Capital Management Inc. now owns 850,132 shares of the basic materials company's stock worth $16,144,000 after buying an additional 35,481 shares during the period. The institutional investor held 375,000 shares of the precious metals company at the end of 2016Q4, valued at $6.04M, up from 225,000 at the end of the previous reported quarter.

The P/E ratio is now 12.75 and the market cap is 17.99B. From the start of year 2017 to present date ABX reported surged performance of 0.38%. The total number of Outstanding Shares is 1.17 Billion. Suncor Energy Inc. (USA) (NYSE:SU) has risen 22.43% since July 25, 2016 and is uptrending. It has underperformed by 5.63% the S&P500. Argus Research upgraded Barrick Gold Corp (USA) (NYSE:ABX) on Tuesday, March 15 to "Buy" rating. The firm earned "Sector Perform" rating on Thursday, December 15 by RBC Capital Markets.

ILLEGAL ACTIVITY WARNING: "Gulf International Bank UK Ltd Has $5.78 Million Stake in Barrick Gold Corporation (ABX)" was first reported by Week Herald and is owned by of Week Herald.

On October 3 the company was set at "Buy" according to a Deutsche Bank report which was a boost from the previous "Hold" rating. As per Monday, April 3, the company rating was maintained by BMO Capital Markets. The firm has "Neutral" rating by JP Morgan given on Wednesday, September 30. As per Thursday, June 15, the company rating was maintained by Raymond James.

Maximum and minimum EPS estimate for the current quarter is projected at $0.26 and $0.12, respectively, according to 14 analysts. ABX's profit will be $242.71M for 18.35 P/E if the $0.21 EPS becomes a reality. After having $0.19 EPS previously, Barrick Gold Corp's analysts see 47.37 % EPS growth. When analyzing at performance throughout recent 6 months we have seen that Barrick Gold Corporation (ABX) is dropping with a downward movement of -13.41%.

On 21 July 2017, Aptose Biosciences Inc. "Be in Your Portfolio?" on July 17, 2017. Accern also gave press coverage about the basic materials company an impact score of 43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Mackenzie Financial Corp now controls 4,234,369 shares with a value of $80,411,000.

The company is expected to report earnings of $0.18 a share for the next quarter. They expect $0.21 EPS, up 50.00% or $0.07 from last year's $0.14 per share.

Among 21 analysts covering CVS Health (NYSE:CVS), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 33% are positive. Banco Santander had 16 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has "Buy" rating by Jefferies given on Friday, April 7. The stock has "Buy" rating by UBS on Wednesday, February 1. The firm has "Hold" rating given on Wednesday, July 22 by Deutsche Bank. The stock has "Reduce" rating by HSBC on Friday, August 14. The company was reinitiated on Thursday, March 10 by Barclays Capital. The company was maintained on Monday, November 2 by Oppenheimer. The firm has "Sell" rating given on Monday, June 20 by Mackie.

10/05/2016 - Barrick Gold Corporation had its " rating reiterated by analysts at Goldman Sachs. As per Wednesday, August 19, the company rating was reinitiated by Evercore.

Investors sentiment is 1.09 in 2016 Q4. Its down 0.30, from 1.01 in 2016Q3. It dived, as 135 investors sold CVS shares while 627 reduced holdings. Valley Advisers invested in 1,648 shares. "Our EPS estimate increases from $0.14 on ACA results, which include an ~$18M share-based expense recovery (excluding the share-based recovery our EPS estimate would've declined to $0.13 on lower ACA sales than prior CS estimate)", contends the analyst.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.